Dimensional and Developmental Profiles of Psychosis in Children and Adolescents
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age7-20
SponsorAssistance Publique - Hôpitaux de Paris
About this trial
Five collaborating sites in France will study the broad spectrum of schizophrenia in children and adolescents. Patients will be studied with diagnostic interviews, developmental histories, dimensional clinical ratings, comprehensive cognitive assessments, neuroimaging and DNA (copy number variant) analyses (in families and patients who agree), and follow-up of course of illness, cognitive status and treatment response to specific antipsychotic drugs. The goal of the study is to test a prior hypothesis about clinical subgroups in this population and to test whether these subgroups predict antipsychotic medication response.
Eligibility criteria
Qualifiers
Children and young adults ages 7-20 years with age of onset of psychotic disorder between 7-17 years.
Hospitalized or seen for out-patient treatment for a psychotic episode, acute or chronic.
DSM-V diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, psychotic disorder not otherwise specified, or major depressive episode with psychotic features.
Written informed consent signed by the parents or the individual(s) with legal parental authority, and by the minor patient if his/her condition permits.
Disqualifiers
Moderate or severe intellectual deficiency (IQ < 50).
Psychoses judged to be secondary to medical illness, medication effects or drugs of abuse.
Diagnosis of bipolar disorder.
Patients who are under legal guardianship.
Trial design
Treatments tested in this trial
- clinical, neuroimaging and DNA assessments
Treatment groups
200 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov